Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Post-Market Leader Stock

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified ACADIA Pharmaceuticals ( ACAD) as a post-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified ACADIA Pharmaceuticals as such a stock due to the following factors:

  • ACAD has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $56.9 million.
  • ACAD is up 2.6% today from today's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ACAD with the Ticky from Trade-Ideas. See the FREE profile for ACAD NOW at Trade-Ideas

More details on ACAD:

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. Currently there are 8 analysts that rate ACADIA Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

The average volume for ACADIA Pharmaceuticals has been 2.2 million shares per day over the past 30 days. ACADIA has a market cap of $3.6 billion and is part of the health care sector and drugs industry. Shares are up 12.4% year-to-date as of the close of trading on Wednesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates ACADIA Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow.

If you liked this article you might like

Biotech M&A: Who's Next After Gilead-Kite?

'Longing' for Acadia Pharmaceuticals? Here's How to Play It

3 Housing Plays With Solid Earnings

7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods

Jana Partners Liquidates Whole Foods Stake After Engineering Industry-Transforming Sale To Amazon